Holen Sie sich die Stockscreener-App
17.67
3.27%
0.56
Handel nachbörslich:
17.46
-0.21
-1.19%
Schlusskurs vom Vortag:
$17.11
Offen:
$17.21
24-Stunden-Volumen:
622.31K
Relative Volume:
0.96
Marktkapitalisierung:
$501.84M
Einnahmen:
$320.35M
Nettoeinkommen (Verlust:
$-75.01M
KGV:
-7.3769
EPS:
-2.3953
Netto-Cashflow:
$-113.17M
1W Leistung:
+10.78%
1M Leistung:
+8.34%
6M Leistung:
-41.39%
1J Leistung:
-13.00%
1-Tages-Spanne:
$17.11
$17.91
1-Wochen-Bereich:
$15.84
$17.91
52-Wochen-Spanne:
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
Firmenname
Fulgent Genetics Inc
Sektor
Branche
Telefon
626-350-0537
Adresse
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
17.67 | 485.93M | 320.35M | -75.01M | -113.17M | -2.3953 |
TMO
Thermo Fisher Scientific Inc
|
448.18 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.81 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.21 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
338.64 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.08 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Hochstufung | UBS | Neutral → Buy |
| 2023-12-07 | Eingeleitet | UBS | Neutral |
| 2022-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-11-18 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Underperform |
| 2021-01-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2020-11-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-08-20 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-29 | Eingeleitet | BTIG Research | Buy |
| 2019-11-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-03-01 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Fulgent Genetics Inc Aktie (FLGT) Neueste Nachrichten
(FLGT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Law firm investigates Fulgent Genetics for possible securities law violations after revenue miss. - Pluang
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics - GlobeNewswire
Fulgent Genetics Presents Promising Phase 2 FID-007 & Cetuximab Data for Head and Neck Cancer at ASCO 2026 - Minichart
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting - BioSpace
Fulgent reports interim data for cancer drug FID-007 trial By Investing.com - Investing.com South Africa
Fulgent reports interim data for cancer drug FID-007 trial - Investing.com
Fulgent Announces ASCO Rapid Oral Abstract Showing 60% ORR, 7.2‑mo mPFS for FID-007 plus Cetuximab - TradingView
Fulgent (NASDAQ: FLGT) reports 60% ORR in Phase 2 FID-007 cancer trial - Stock Titan
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
Fulgent Genetics targets wider engagement at APG2026 San Diego exhibit fair - Traders Union
FLGT Stock Chart | FULGENT GENETICS INC (NASDAQ:FLGT) - ChartMill
Fulgent Genetics (FLGT) director receives stock units and 8,426-share option grant - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) director receives 11,117 RSUs - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) director awarded 11,117 restricted stock units - Stock Titan
Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87 - MSN
Fulgent Genetics Shareholders Approve New 2026 Equity Plan - TipRanks
Fulgent Genetics (NASDAQ: FLGT) wins stockholder approval for 2026 equity plan - Stock Titan
ETFs Investing in Fulgent Genetics, Inc. Stocks - TradingView
Responsive Playbooks and the FLGT Inflection - Stock Traders Daily
Fulgent Genetics infertility test panels broaden to cover over 140 genes for females and 160 for males - Traders Union
TradingKey - TradingKey
LA500 2026: Ming Hsieh - Los Angeles Business Journal
Fulgent Genetics (NASDAQ:FLGT) Stock Passes Below Fifty Day Moving AverageHere's Why - MarketBeat
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - The Globe and Mail
Number of shareholders of Fulgent Genetics, Inc. – NASDAQ:FLGT - TradingView
Fulgent (FLGT) Q1 2026 Earnings Transcript - AOL.com
SEC EDGAR Submission 0000950170-25-062257 - SEC.gov
How many employees work at Fulgent Therapeutics? - Revelio Labs
Foundation Medicine links with Fulgent Genetics to offer new gene test - Fierce Biotech
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - BioSpace
PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - Business Wire
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2026 Earnings Call Transcript - Insider Monkey
Fulgent Q1 2026 slides: revenue misses amid customer loss, therapy data shines - Investing.com Nigeria
Fulgent Genetics Reports Q1 2026 Results: $71M Revenue, Stock Buyback, Updated Guidance and Progress in Cancer Therapeutics - Minichart
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Na - GuruFocus
Understanding the Setup: (FLGT) and Scalable Risk - Stock Traders Daily
Fulgent Genetics, Inc. Q1 2026 SEC 10-Q Filing: Financial Statements, Company Information, and Risk Disclosure - Minichart
Fulgent Genetics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Is Fulgent Genetics (FLGT) 38.5% Undervalued After Q1 2026? Reve - GuruFocus
Fulgent outlines $350M 2026 revenue outlook following Bako/StrataDx acquisition - MSN
Fulgent Genetics, Inc. (FLGT) reports Q1 loss, beats revenue estimates - MSN
Fulgent Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fulgent Genetics Posts Q1 Loss, Reaffirms 2026 Outlook - TipRanks
Fulgent Genetics 1Q 2026: Revenue $71.1M, Net loss $(24.8)M, EPS $(0.80) — 10-Q Summary - TradingView
Fulgent Genetics Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Fulgent Genetics disappoints with Q1 2026 results By Investing.com - Investing.com South Africa
Fulgent Reports First Quarter 2026 Financial Results - The National Law Review
Fulgent Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Finanzdaten der Fulgent Genetics Inc-Aktie (FLGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fulgent Genetics Inc-Aktie (FLGT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gao Hanlin | Chief Scientific Officer |
Dec 02 '25 |
Sale |
28.33 |
1,075 |
30,457 |
952,890 |
| Xie Jian | President and COO |
Nov 28 '25 |
Sale |
29.57 |
1,198 |
35,424 |
337,889 |
| Gao Hanlin | Chief Scientific Officer |
Nov 28 '25 |
Sale |
29.57 |
943 |
27,884 |
953,965 |
1.19%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):